PET Imaging of Angiogenesis

PET Clinics

Volumn 4, Issue 1, 2009, Pages 17-38

  Niu, Gang ^a   Chen, Xiaoyuan ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Integrin; MMP; Molecular imaging; VEGFR

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; AXITINIB; BEVACIZUMAB; CARBON 11; CARBON MONOXIDE; CARBOXYHEMOGLOBIN; COPPER 64; FLUORINE 18; GADOLINIUM PENTETATE; GALLIUM 68; INDIUM 111; INTEGRIN; MACROGOL; RHENIUM 188; SEMAXANIB; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SORAFENIB; SUNITINIB; TECHNETIUM 99M; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1; WATER O 15; YTTRIUM 90;

ANGIOGENESIS; BLOOD FLOW VELOCITY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST ENHANCEMENT; DRUG DESIGN; DRUG EFFICACY; ECHOGRAPHY; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MALIGNANT NEOPLASTIC DISEASE; MICROSCOPY; MOLECULAR MECHANICS; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

EID: 68349083476     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.04.011     Document Type: Review

References (208)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 1 (1995) 27-31
2. Atluri P., and Woo Y.J. Pro-angiogenic cytokines as cardiovascular therapeutics: assessing the potential. BioDrugs 22 4 (2008) 209-222
3. Pathak A.P., Gimi B., Glunde K., et al. Molecular and functional imaging of cancer: advances in MRI and MRS. Methods Enzymol 386 (2004) 3-60
4. Rajagopalan S., Trachtenberg J., Mohler E., et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol 90 5 (2002) 512-516
5. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 4 (2004) 581-611
6. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
7. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 312 5777 (2006) 1171-1175
8. Faivre S., Demetri G., Sargent W., et al. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6 9 (2007) 734-745
9. Jaffe C.C. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24 20 (2006) 3245-3251
10. Cai W., Rao J., Gambhir S.S., et al. How molecular imaging is speeding up anti-angiogenic drug development. Mol Cancer Ther 5 11 (2006) 2624-2633
11. Choe Y.S., and Lee K.H. Targeted in vivo imaging of angiogenesis: present status and perspectives. Curr Pharm Des 13 1 (2007) 17-31
12. Haubner R. Noninvasive tracer techniques to characterize angiogenesis. Handb Exp Pharmacol 185 II (2008) 323-339
13. Berthelot T., Lasne M.C., and Deleris G. New trends in molecular imaging of tumor angiogenesis. Anticancer Agents Med Chem 8 5 (2008) 497-522
14. Auguste P., Lemiere S., Larrieu-Lahargue F., et al. Molecular mechanisms of tumor vascularization. Crit Rev Oncol Hematol 54 1 (2005) 53-61
15. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6 4 (2000) 389-395
16. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 5422 (1999) 1994-1998
17. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 21 (1971) 1182-1186
18. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3 6 (2003) 422-433
19. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 6 (2003) 401-410
20. Nguyen M. Angiogenic factors as tumor markers. Invest New Drugs 15 1 (1997) 29-37
21. Landgren E., Schiller P., Cao Y., et al. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene 16 3 (1998) 359-367
22. Nor J.E., Christensen J., Mooney D.J., et al. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154 2 (1999) 375-384
23. Paku S., and Paweletz N. First steps of tumor-related angiogenesis. Lab Invest 65 3 (1991) 334-346
24. Djonov V., Schmid M., Tschanz S.A., et al. Intussusceptive angiogenesis: its role in embryonic vascular network formation. Circ Res 86 3 (2000) 286-292
25. Metzger R.J., and Krasnow M.A. Genetic control of branching morphogenesis. Science 284 5420 (1999) 1635-1639
26. Pepper M.S., Ferrara N., Orci L., et al. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181 2 (1991) 902-906
27. Asahara T., Chen D., Takahashi T., et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83 3 (1998) 233-240
28. 3 for angiogenesis. Science 264 5158 (1994) 569-571
29. Friedlander M., Brooks P.C., Shaffer R.W., et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270 5241 (1995) 1500-1502
30. Sang Q.X. Complex role of matrix metalloproteinases in angiogenesis. Cell Res 8 3 (1998) 171-177
31. Gamble J., Meyer G., Noack L., et al. B1 integrin activation inhibits in vitro tube formation: effects on cell migration, vacuole coalescence and lumen formation. Endothelium 7 1 (1999) 23-34
32. Nakao N., Miura K., Takayasu Y., et al. CT angiography in hepatocellular carcinoma. J Comput Assist Tomogr 7 5 (1983) 780-787
33. Less J.R., Skalak T.C., Sevick E.M., et al. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51 1 (1991) 265-273
34. Konerding M.A., Miodonski A.J., and Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc 9 4 (1995) 1233-1243
35. Schlingemann R.O., Rietveld F.J., Kwaspen F., et al. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol 138 6 (1991) 1335-1347
36. Miettinen M., Lindenmayer A.E., and Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens-evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 7 1 (1994) 82-90
37. Schlaeger T.M., Bartunkova S., Lawitts J.A., et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A 94 7 (1997) 3058-3063
38. Motoike T., Loughna S., Perens E., et al. Universal GFP reporter for the study of vascular development. Genesis 28 2 (2000) 75-81
39. Trotter M.J., Olive P.L., and Chaplin D.J. Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse. Br J Cancer 62 6 (1990) 903-908
40. Hashizume H., Baluk P., Morikawa S., et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156 4 (2000) 1363-1380
41. Usami N., Iwano S., and Yokoi K. Solitary fibrous tumor of the pleura: evaluation of the origin with 3D CT angiography. J Thorac Oncol 2 12 (2007) 1124-1125
42. McDonald D.M., and Choyke P.L. Imaging of angiogenesis: from microscope to clinic. Nat Med 9 6 (2003) 713-725
43. van Vliet M., van Dijke C.F., Wielopolski P.A., et al. MR angiography of tumor-related vasculature: from the clinic to the micro-environment. Radiographics 25 Suppl 1 (2005) S85-S97 [discussion: S97-8]
44. Boudghene F.P., Gouny P., Tassart M., et al. Subungual glomus tumor: combined use of MRI and three-dimensional contrast MR angiography. J Magn Reson Imaging 8 6 (1998) 1326-1328
45. Foster F.S., Burns P.N., Simpson D.H., et al. Ultrasound for the visualization and quantification of tumor microcirculation. Cancer Metastasis Rev 19 1-2 (2000) 131-138
46. Jiang Y., Zhao J., White D.L., et al. Micro CT and Micro MR imaging of 3D architecture of animal skeleton. J Musculoskelet Neuronal Interact 1 1 (2000) 45-51
47. Tozer G.M., Ameer-Beg S.M., Baker J., et al. Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. Adv Drug Deliv Rev 57 1 (2005) 135-152
48. Galbraith S.M. Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development. Br J Radiol 76 Spec No 1 (2003) S83-S86
49. Choyke P.L., Dwyer A.J., and Knopp M.V. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 17 5 (2003) 509-520
50. O'Connor J.P., Jackson A., Parker G.J., et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96 2 (2007) 189-195
51. Zhang C., Jugold M., Woenne E.C., et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 67 4 (2007) 1555-1562
52. Liu G., Rugo H.S., Wilding G., et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 23 24 (2005) 5464-5473
53. Thomas A.L., Morgan B., Horsfield M.A., et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23 18 (2005) 4162-4171
54. Medved M., Karczmar G., Yang C., et al. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging 20 1 (2004) 122-128
55. Padhani A.R. MRI for assessing antivascular cancer treatments. Br J Radiol 76 Spec No 1 (2003) S60-S80
56. Marzola P., Degrassi A., Calderan L., et al. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 10 2 (2004) 739-750
57. Faccioli N., Marzola P., Boschi F., et al. Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging. Radiol Med (Torino) 112 3 (2007) 319-328
58. Williams D.S. Quantitative perfusion imaging using arterial spin labeling. Methods Mol Med 124 (2006) 151-173
59. Liu T.T., and Brown G.G. Measurement of cerebral perfusion with arterial spin labeling: Part 1. Methods. J Int Neuropsychol Soc 13 3 (2007) 517-525
60. Wolf R.L., and Detre J.A. Clinical neuroimaging using arterial spin-labeled perfusion magnetic resonance imaging. Neurotherapeutics 4 3 (2007) 346-359
61. Hsu Y.Y., Chang C.N., Jung S.M., et al. Blood oxygenation level-dependent MRI of cerebral gliomas during breath holding. J Magn Reson Imaging 19 2 (2004) 160-167
62. Baudelet C., Cron G.O., and Gallez B. Determination of the maturity and functionality of tumor vasculature by MRI: correlation between BOLD-MRI and DCE-MRI using P792 in experimental fibrosarcoma tumors. Magn Reson Med 56 5 (2006) 1041-1049
63. Fleischer A.C., Wojcicki W.E., Donnelly E.F., et al. Quantified color Doppler sonography of tumor vascularity in an animal model. J Ultrasound Med 18 8 (1999) 547-551
64. Forsberg F., Ro R.J., Potoczek M., et al. Assessment of angiogenesis: implications for ultrasound imaging. Ultrasonics 42 1-9 (2004) 325-330
65. Drevs J., Hofmann I., Hugenschmidt H., et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60 17 (2000) 4819-4824
66. Liang J.D., Yang P.M., Liang P.C., et al. Three-dimensional power Doppler ultrasonography for demonstrating associated arteries of hepatocellular carcinoma. J Formos Med Assoc 102 6 (2003) 367-374
67. Stride E., and Saffari N. Microbubble ultrasound contrast agents: a review. Proc Inst Mech Eng [H] 217 6 (2003) 429-447
68. Niermann K.J., Fleischer A.C., Huamani J., et al. Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 26 6 (2007) 749-756
69. Wilson S.R., Burns P.N., Muradali D., et al. Harmonic hepatic US with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma, and metastasis. Radiology 215 1 (2000) 153-161
70. Burns P.N., Wilson S.R., and Simpson D.H. Pulse inversion imaging of liver blood flow: improved method for characterizing focal masses with microbubble contrast. Invest Radiol 35 1 (2000) 58-71
71. Quaia E. Microbubble ultrasound contrast agents: an update. Eur Radiol 17 8 (2007) 1995-2008
72. Cornud F., Hamida K., Flam T., et al. Endorectal color Doppler sonography and endorectal MR imaging features of nonpalpable prostate cancer: correlation with radical prostatectomy findings. Am J Roentgenol 175 4 (2000) 1161-1168
73. McCarville M.B., Streck C.J., Dickson P.V., et al. Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. Radiology 240 1 (2006) 73-81
74. Stieger S.M., Bloch S.H., Foreman O., et al. Ultrasound assessment of angiogenesis in a matrigel model in rats. Ultrasound Med Biol 32 5 (2006) 673-681
75. Ferrara K.W., Merritt C.R., Burns P.N., et al. Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. Acad Radiol 7 10 (2000) 824-839
76. Hughes M.S., Marsh J.N., Zhang H., et al. Characterization of digital waveforms using thermodynamic analogs: detection of contrast-targeted tissue in vivo. IEEE Trans Ultrason Ferroelectr Freq Control 53 9 (2006) 1609-1616
77. Lassau N., Lamuraglia M., Chami L., et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. Am J Roentgenol 187 5 (2006) 1267-1273
78. Li P.C., and Yang M.J. Transfer function analysis of ultrasonic time-intensity measurements. Ultrasound Med Biol 29 10 (2003) 1493-1500
79. Lavisse S., Lejeune P., Rouffiac V., et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 43 2 (2008) 100-111
80. Haider M.A., Milosevic M., Fyles A., et al. Assessment of the tumor microenvironment in cervix cancer using dynamic contrast enhanced CT, interstitial fluid pressure and oxygen measurements. Int J Radiat Oncol Biol Phys 62 4 (2005) 1100-1107
81. Bisdas S., Konstantinou G.N., Lee P.S., et al. Dynamic contrast-enhanced CT of head and neck tumors: perfusion measurements using a distributed-parameter tracer kinetic model. Initial results and comparison with deconvolution-based analysis. Phys Med Biol 52 20 (2007) 6181-6196
82. Larson D.R., Zipfel W.R., Williams R.M., et al. Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science 300 5624 (2003) 1434-1436
83. Brown E.B., Campbell R.B., Tsuzuki Y., et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 7 7 (2001) 864-868
84. Montet X., Ntziachristos V., Grimm J., et al. Tomographic fluorescence mapping of tumor targets. Cancer Res 65 14 (2005) 6330-6336
85. Jones T. The imaging science of positron emission tomography. Eur J Nucl Med 23 7 (1996) 807-813
86. Laking G.R., and Price P.M. Positron emission tomographic imaging of angiogenesis and vascular function. Br J Radiol 76 Spec No 1 (2003) S50-S59
87. Phelps M.E., Hoffman E.J., Mullani N.A., et al. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 16 3 (1975) 210-224
88. Phelps M.E. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 41 4 (2000) 661-681
89. Willmann J.K., van Bruggen N., Dinkelborg L.M., et al. Molecular imaging in drug development. Nat Rev Drug Discov 7 7 (2008) 591-607
90. Beyer T., Townsend D.W., Brun T., et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 41 8 (2000) 1369-1379
91. Kamel E., Hany T.F., Burger C., et al. CT vs 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current. Eur J Nucl Med Mol Imaging 29 3 (2002) 346-350
92. Cherry S.R., Shao Y., Silverman R.W., et al. MicroPET: a high resolution PET scanner for imaging small animals. IEEE Trans Nucl Sci 44 3 (1997) 1161-1166
93. Chatziioannou A.F., Cherry S.R., Shao Y., et al. Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. J Nucl Med 40 7 (1999) 1164-1175
94. Pichler B.J., Judenhofer M.S., and Pfannenberg C. Multimodal imaging approaches: PET/CT and PET/MRI. Handb Exp Pharmacol 185 I (2008) 109-132
95. Laking G.R., West C., Buckley D.L., et al. Imaging vascular physiology to monitor cancer treatment. Crit Rev Oncol Hematol 58 2 (2006) 95-113
96. Anderson R.E. Cerebral blood flow xenon-133. Neurosurg Clin N Am 7 4 (1996) 703-708
97. Wilson R.A., Shea M.J., De Landsheere C.M., et al. Validation of quantitation of regional myocardial blood flow in vivo with 11C-labeled human albumin microspheres and positron emission tomography. Circulation 70 4 (1984) 717-723
98. 15O-water using compartment and noncompartment analysis. J Nucl Med 42 2 (2001) 248-256
99. Acierno L.J. Adolph Fick: mathematician, physicist, physiologist. Clin Cardiol 23 5 (2000) 390-391
100. Lammertsma A.A., and Jones T. Low oxygen extraction fraction in tumours measured with the oxygen-15 steady state technique: effect of tissue heterogeneity. Br J Radiol 65 776 (1992) 697-700
101. Iida H., Takahashi A., Tamura Y., et al. Myocardial blood flow: comparison of oxygen-15-water bolus injection, slow infusion and oxygen-15-carbon dioxide slow inhalation. J Nucl Med 36 1 (1995) 78-85
102. Wilson C.B., Lammertsma A.A., McKenzie C.G., et al. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 52 6 (1992) 1592-1597
103. Anderson H., and Price P. Clinical measurement of blood flow in tumours using positron emission tomography: a review. Nucl Med Commun 23 2 (2002) 131-138
104. Tseng J., Dunnwald L.K., Schubert E.K., et al. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 45 11 (2004) 1829-1837
105. Hoffend J., Mier W., Schuhmacher J., et al. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nucl Med Biol 32 3 (2005) 287-292
106. Sipkins D.A., Cheresh D.A., Kazemi M.R., et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 4 5 (1998) 623-626
107. Wierzbicka-Patynowski I., Niewiarowski S., Marcinkiewicz C., et al. Structural requirements of echistatin for the recognition of alpha vbeta 3 and alpha 5beta 1 Integrins. J Biol Chem 274 53 (1999) 37809-37814
108. Cai W., Shin D.W., Chen K., et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 6 4 (2006) 669-676
109. Hood J.D., and Cheresh D.A. Role of integrins in cell invasion and migration. Nat Rev Cancer 2 2 (2002) 91-100
110. Chen X. Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev Med Chem 6 2 (2006) 227-234
111. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 110 6 (2002) 673-687
112. 3 in complex with an Arg-Gly-Asp ligand. Science 296 5565 (2002) 151-155
113. Ruoslahti E., and Pierschbacher M.D. New perspectives in cell adhesion: RGD and integrins. Science 238 4826 (1987) 491-497
114. Jin H., and Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 90 3 (2004) 561-565
115. Mizejewski G.J. Role of integrins in cancer: survey of expression patterns (44435). Proc Soc Exp Biol Med 222 2 (1999) 124-138
116. 3 antagonism. Anticancer Agents Med Chem 6 (2006) 407-428
117. 3. Cell 85 5 (1996) 683-693
118. 5 integrin-deficient mice. Development 119 4 (1993) 1093-1105
119. 5 integrin-null embryos. Development 124 21 (1997) 4309-4319
120. 5-integrin-negative teratocarcinomas and embryoid bodies. Cancer Res 61 13 (2001) 5255-5261
121. 4 integrins are essential in placental and cardiac development. Development 121 2 (1995) 549-560
122. Aumailley M., Gurrath M., Muller G., et al. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 291 1 (1991) 50-54
123. 3 integrin for a new cancer therapy. Angew Chem Int Ed Engl 36 (1997) 1374-1389
124. Haubner R., Wester H.J., Reuning U., et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 40 6 (1999) 1061-1071
125. Haubner R., Wester H.J., Weber W.A., et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61 5 (2001) 1781-1785
126. Haubner R. Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis?. Eur J Nucl Med Mol Imaging 33 Suppl 1 (2006) 54-63
127. Harris J.M., Martin N.E., and Modi M. PEGylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40 7 (2001) 539-551
128. Chen X., Park R., Shahinian A.H., et al. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31 1 (2004) 11-19
129. Noiri E., Goligorsky M.S., Wang G.J., et al. Biodistribution and clearance of 99mTc-labeled Arg-Gly-Asp (RGD) peptide in rats with ischemic acute renal failure. J Am Soc Nephrol 7 12 (1996) 2682-2688
130. Chen X., Hou Y., Tohme M., et al. PEGylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med 45 10 (2004) 1776-1783
131. Dijkgraaf I., Liu S., Kruijtzer J.A., et al. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Nucl Med Biol 34 1 (2007) 29-35
132. Li Z.B., Chen K., and Chen X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging 35 6 (2008) 1100-1108
133. van Hagen P.M., Breeman W.A., Bernard H.F., et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 90 4 (2000) 186-198
134. Bach-Gansmo T., Danielsson R., Saracco A., et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med 47 9 (2006) 1434-1439
135. Haubner R., Wester H.J., Burkhart F., et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42 2 (2001) 326-336
136. Haubner R., Kuhnast B., Mang C., et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15 1 (2004) 61-69
137. Haubner R., Weber W.A., Beer A.J., et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2 3 (2005) e70
138. Beer A.J., Haubner R., Goebel M., et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 46 8 (2005) 1333-1341
139. Beer A.J., Haubner R., Wolf I., et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 47 5 (2006) 763-769
140. Beer A.J., Haubner R., Sarbia M., et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 12 13 (2006) 3942-3949
141. Beer A.J., Grosu A.L., Carlsen J., et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13 22 Pt 1 (2007) 6610-6616
142. Beer A.J., Lorenzen S., Metz S., et al. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med 49 1 (2008) 22-29
143. Boturyn D., Coll J.L., Garanger E., et al. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J Am Chem Soc 126 18 (2004) 5730-5739
144. Chen X., Tohme M., Park R., et al. Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 3 2 (2004) 96-104
145. Zhang X., Xiong Z., Wu Y., et al. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med 47 1 (2006) 113-121
146. Chen X., Park R., Tohme M., et al. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 15 1 (2004) 41-49
147. Chen X., Liu S., Hou Y., et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 6 5 (2004) 350-359
148. Wu Z., Li Z.B., Chen K., et al. MicroPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med 48 9 (2007) 1536-1544
149. Li Z.B., Cai W., Cao Q., et al. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 48 7 (2007) 1162-1171
150. Thumshirn G., Hersel U., Goodman S.L., et al. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry 9 12 (2003) 2717-2725
151. Poethko T., Schottelius M., Thumshirn G., et al. Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J Nucl Med 45 5 (2004) 892-902
152. Cai W., Wu Y., Chen K., et al. In vitro and in vivo characterization of 64Cu-labeled AbegrinTM, a humanized monoclonal antibody against integrin avb3. Cancer Res 66 19 (2006) 9673-9681
153. Higuchi T., Bengel F.M., Seidl S., et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res 78 2 (2008) 395-403
154. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2 10 (2002) 795-803
155. Broumas A.R., Pollard R.E., Bloch S.H., et al. Contrast-enhanced computed tomography and ultrasound for the evaluation of tumor blood flow. Invest Radiol 40 3 (2005) 134-147
156. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 5 (2005) 1011-1027
157. Sun J., Wang D.A., Jain R.K., et al. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 24 29 (2005) 4701-4709
158. Watanabe H., Mamelak A.J., Wang B., et al. Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity. Exp Dermatol 13 11 (2004) 671-681
159. Prewett M., Huber J., Li Y., et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59 20 (1999) 5209-5218
160. Ciardiello F., Caputo R., Damiano V., et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9 4 (2003) 1546-1556
161. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60 4 (2000) 970-975
162. Kennedy J.E., ter Haar G.R., Wu F., et al. Contrast-enhanced ultrasound assessment of tissue response to high-intensity focused ultrasound. Ultrasound Med Biol 30 6 (2004) 851-854
163. Cai W., and Chen X. Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci 12 (2007) 4267-4279
164. Nagengast W.B., de Vries E.G., Hospers G.A., et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48 8 (2007) 1313-1319
165. 124I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62 20 (2002) 5912-5919
166. Jayson G.C., Zweit J., Jackson A., et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94 19 (2002) 1484-1493
167. Scheer M.G., Stollman T.H., Boerman O.C., et al. Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. Eur J Cancer 44 13 (2008) 1835-1840
168. Strauss L.G., Koczan D., Klippel S., et al. Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors. J Nucl Med 49 8 (2008) 1238-1244
169. Hsu A.R., Cai W., Veeravagu A., et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med 48 3 (2007) 445-454
170. Cai W., Chen K., Mohamedali K.A., et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 47 12 (2006) 2048-2056
171. Chen K., Cai W., Li Z.B., et al. Quantitative PET Imaging of VEGF receptor expression. Mol Imaging Biol 11 1 (2008) 15-22
172. Backer M.V., Levashova Z., Patel V., et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med 13 4 (2007) 504-509
173. Li J., Brown L.F., Hibberd M.G., et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 270 5 Pt 2 (1996) H1803-H1811
174. Soeki T., Tamura Y., Shinohara H., et al. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology 93 3 (2000) 168-174
175. Rodriguez-Porcel M., Cai W., Gheysens O., et al. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med 49 4 (2008) 667-673
176. Willmann J.K., Paulmurugan R., Chen K., et al. Ultrasonic imaging of tumor angiogenesis with contrast microbubbles targeted to vascular endothelial growth factor type 2 receptor. [revision]. Radiology 246 2 (2007) 508-518
177. Cai W., Guzman R., Hsu A.R., et al. Positron emission tomography imaging of poststroke angiogenesis. Stroke 40 1 (2008) 270-277
178. Simon M., Rockl W., Hornig C., et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. J Am Soc Nephrol 9 6 (1998) 1032-1044
179. Keyt B.A., Nguyen H.V., Berleau L.T., et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 271 10 (1996) 5638-5646
180. Wang H., Cai W., Chen K., et al. A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 34 12 (2007) 2001-2010
181. Wagner S., Breyholz H.J., Faust A., et al. Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET. Curr Med Chem 13 23 (2006) 2819-2838
182. Folgueras A.R., Pendas A.M., Sanchez L.M., et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48 5-6 (2004) 411-424
183. Johnson J.L., George S.J., Newby A.C., et al. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A 102 43 (2005) 15575-15580
184. Hidalgo M., and Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93 3 (2001) 178-193
185. Li W.P., and Anderson C.J. Imaging matrix metalloproteinase expression in tumors. Q J Nucl Med 47 3 (2003) 201-208
186. Lee S., Park K., Kim K., et al. Activatable imaging probes with amplified fluorescent signals. Chem Commun (Camb) 36 (2008) 4250-4260
187. Lee S., Park K., Lee S.Y., et al. Dark quenched matrix metalloproteinase fluorogenic probe for imaging osteoarthritis development in vivo. Bioconjug Chem 19 9 (2008) 1743-1747
188. Bremer C., Bredow S., Mahmood U., et al. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 221 2 (2001) 523-529
189. Medina O.P., Kairemo K., Valtanen H., et al. Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide. Anticancer Res 25 1A (2005) 33-42
190. Hanaoka H., Mukai T., Habashita S., et al. Chemical design of a radiolabeled gelatinase inhibitor peptide for the imaging of gelatinase activity in tumors. Nucl Med Biol 34 5 (2007) 503-510
191. Sprague J.E., Li W.P., Liang K., et al. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nucl Med Biol 33 2 (2006) 227-237
192. Zheng Q.H., Fei X., Liu X., et al. Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol 29 7 (2002) 761-770
193. Furumoto S., Takashima K., Kubota K., et al. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol 30 2 (2003) 119-125
194. Wagner S., Breyholz H.J., Law M.P., et al. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET. J Med Chem 50 23 (2007) 5752-5764
195. Zheng Q.H., Fei X., Liu X., et al. Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4′-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4′-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbut anamide. Nucl Med Biol 31 1 (2004) 77-85
196. Zheng Q.H., Fei X., DeGrado T.R., et al. Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester. Nucl Med Biol 30 7 (2003) 753-760
197. Kulasegaram R., Giersing B., Page C.J., et al. In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection. Eur J Nucl Med 28 6 (2001) 756-761
198. Neri D., Carnemolla B., Nissim A., et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 15 12 (1997) 1271-1275
199. Santimaria M., Moscatelli G., Viale G.L., et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 9 2 (2003) 571-579
200. Suri C., Jones P.F., Patan S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87 7 (1996) 1171-1180
201. Seaman S., Stevens J., Yang M.Y., et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11 6 (2007) 539-554
202. Shao Y., Cherry S.R., Farahani K., et al. Simultaneous PET and MR imaging. Phys Med Biol 42 10 (1997) 1965-1970
203. Townsend D.W., and Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol 75 Spec No (2002) S24-S30
204. Catana C., Wu Y., Judenhofer M.S., et al. Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. J Nucl Med 47 12 (2006) 1968-1976
205. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34 (2007) 850-858 [Epub]
206. Cai W., Ebrahimnejad A., Chen K., et al. Quantitative radioimmunoPET imaging of EphA2 in tumour-bearing mice. Eur J Nucl Med Mol Imaging 34 12 (2007) 2024-2036
207. Li Z.B., Wu Z., Chen K., et al. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med 49 3 (2008) 453-461
208. Jung K.H., Lee K.H., Paik J.Y., et al. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med 47 12 (2006) 2000-2007